Computer Modeling of Diabetes and Its Complications
暂无分享,去创建一个
John Hornberger | J. Hornberger | R. Coleman | Philip Clarke | William J. Valentine | Andrew J. Palmer | Adrian Bagust | P. McEwan | Stéphane Roze | M. Gillett | Michael Holmes | Richard Stevens | Alastair M Gray | S. Sorensen | E. Müller | S. Walzer | D. M. Eddy | Richard Kahn | Jonathan B. Brown
[1] Deanna J. M. Isaman,et al. A computer simulation model of diabetes progression, quality of life, and cost. , 2005, Diabetes care.
[2] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. , 1995, Kidney international.
[3] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[4] Y. Hamamoto,et al. Guidelines for computer modeling of diabetes and its complications. , 2004, Diabetes care.
[5] S. Pocock,et al. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.
[6] Stephen W. Sorensen,et al. The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance , 2005, Annals of Internal Medicine.
[7] Volker Foos,et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. , 2004, Current medical research and opinion.
[8] R. Holman,et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.
[9] Volker Foos,et al. The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making , 2004, Current medical research and opinion.
[10] M. Vardi,et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. , 2010, Pharmacogenomics.
[11] Stephen J. Aldington,et al. UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis , 2001, Diabetologia.
[12] A J Palmer,et al. The Mt. Hood challenge: cross-testing two diabetes simulation models. , 2000, Diabetes research and clinical practice.
[13] R. Holman,et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) , 2004, Diabetologia.
[14] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[15] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[16] C. Byrne,et al. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[17] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[18] Rury R Holman,et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.
[19] Klas Bergenheim,et al. Assessing the Relationship between Computational Speed and Precision , 2012, PharmacoEconomics.
[20] S. Weinstein. Fifty years of somatosensory research: from the Semmes-Weinstein monofilaments to the Weinstein Enhanced Sensory Test. , 1993, Journal of hand therapy : official journal of the American Society of Hand Therapists.
[21] J. Peters,et al. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster) , 2006, Current medical research and opinion.
[22] J. Peters,et al. Evaluating the performance of the Framingham risk equations in a population with diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[23] Ping Zhang,et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[24] M. Evans,et al. Understanding the inter‐relationship between improved glycaemic control, hypoglycaemia and weight change within a long‐term economic model , 2010, Diabetes, obesity & metabolism.
[25] Richard Stevens,et al. Evaluation of methods for interval estimation of model outputs, with application to survival models , 2003 .
[26] C. Chatfield. Model uncertainty, data mining and statistical inference , 1995 .
[27] N. Freemantle,et al. Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. , 2006, Diabetes technology & therapeutics.
[28] Irene M Stratton,et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. , 2004, Diabetes care.
[29] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.
[30] Kevin A Peterson,et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .
[31] Zara L Whitlock,et al. Additional contributions by , 1979 .
[32] K. Yeo,et al. Predicting CHD risk in patients with diabetes mellitus , 2001, Diabetic medicine : a journal of the British Diabetic Association.
[33] The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. , 1995, Archives of ophthalmology.
[34] The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy , 1995, Annals of Internal Medicine.
[35] Vincent R. Gray. Climate Change 2007: The Physical Science Basis Summary for Policymakers , 2007 .
[36] David M Eddy,et al. Archimedes: a trial-validated model of diabetes. , 2003, Diabetes care.
[37] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[38] The Absence of a Glycemic Threshold for the Development of Long-Term Complications: The Perspective of the Diabetes Control and Complications Trial , 1996, Diabetes.
[39] R. Holman,et al. A Cardiovascular Risk Calculator for Type 2 Diabetes , 2005 .
[40] Donghee Lee,et al. Chronic disease modeling and simulation software , 2010, J. Biomed. Informatics.
[41] R. Stevens,et al. UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine , 2002, Stroke.
[42] Stephen W. Sorensen,et al. Validation of the CDC-RTI diabetes cost-effectiveness model , 2009 .
[43] Anke Richter,et al. Optimal Allocation of Resources across Four Interventions for Type 2 Diabetes , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.
[44] J. Wylie-Rosett,et al. Implementation of Treatment Protocols in the Diabetes Control and Complications Trial , 1995, Diabetes Care.
[45] M I Mackness,et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[46] R. Holman,et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.
[47] Anke Richter,et al. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. , 2002, JAMA.
[48] David M Eddy,et al. Validation of the archimedes diabetes model. , 2003, Diabetes care.
[49] M. Willis,et al. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. , 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[50] Stephen W. Sorensen,et al. Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis , 2004, Annals of Internal Medicine.